Latest News About Pancreatic Cancer

Here are the latest developments on pancreatic cancer from credible sources available up to May 2026.

• FDA expanded access and new treatment approvals in 2026: An FDA expansion to provide access to a promising pancreatic cancer drug (Daraxonrasib) after showing survival benefits in advanced disease, and an FDA approval of a wearable device used with chemotherapy for locally advanced pancreatic cancer. These reflect ongoing efforts to extend survival and broaden treatment options in carefully selected patients.[1]
• New targeted therapies and approvals for pancreatic neuroendocrine tumors (PNETs): The FDA approved a targeted therapy for NRG1 fusion-positive pancreatic cancer and another approval related to PNETs, signaling continued expansion of precision medicine in pancreatic cancer subtypes (PNETs).[1]
• Survival and early detection concerns: Pancreatic cancer diagnoses and mortality remain high with a 5-year survival rate around 13%, highlighting the ongoing need for early detection and novel therapeutics.[1]
• Research and investment activity: PanCAN and related organizations are continuing to fund and announce research grants, particularly in early detection and novel therapies, as federal funding challenges persist.[1]

Key sources you can consult for more detail:

• PanCAN News and Blog: latest updates on approvals, trials, and policy developments in pancreatic cancer care.[1]
• CBS News and other major outlets: coverage of new treatments and FDA actions that impact pancreatic cancer patients,.[3][4]
• ScienceDaily and local research news: summaries of breakthrough studies in immunotherapy and early detection approaches.[7]

If you’d like, I can summarize a specific article, pull a brief timeline of approvals in 2025–2026, or compile a one-page handout of current treatment options by disease stage.